NEW YORK, July 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding IDEXX Laboratories, Inc. (NASDAQ: IDXX), AmSurg Corp (NASDAQ: AMSG), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Opko Health Inc. (NYSE: OPK) and PerkinElmer, Inc. (NYSE: PKI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4743-100free.
IDEXX Laboratories, Inc. Analyst Notes
On July 8, 2014, IDEXX Laboratories, Inc. (IDEXX Laboratories) introduced a next-generation intestinal parasite test called ELISA or enzyme-linked immunosorbent assay, which detects more whipworm infections in dogs earlier than current diagnostic methods. According to the Company, this is the only test capable of directly detecting the presence of an adult whipworm parasite. The Company stated that the data collected through IDEXX Reference Laboratories reveals that the Whipworm Antigen ELISA can detect more than twice the number of infections in dogs when the ELISA is run with the traditional ova and parasite testing, resulting to earlier diagnosis, management, and treatment. The full analyst notes on IDEXX Laboratories are available to download free of charge at:
http://www.analystsreview.com/Jul-14-2014/IDXX/report.pdf
AmSurg Corp Analyst Notes
On July 3, 2014, AmSurg Corp (AmSurg) announced that it will release its Q2 2014 financial results on Thursday, July 31, 2014, after the market closes, and will also host a conference call on the same day at 5:00 p.m. ET. According to the Company, a live webcast of the call will be accessible through its website. A replay of the call will be available after the completion of the call, and will remain on AmSurg 's website for 30 days. The full analyst notes on AmSurg are available to download free of charge at:
http://www.analystsreview.com/Jul-14-2014/AMSG/report.pdf
Aegerion Pharmaceuticals, Inc. Analyst Notes
On July 9, 2014, Aegerion Pharmaceuticals, Inc. (Aegerion Pharmaceuticals) announced that on July 1, 2014, it granted stock options to purchase an aggregate of 40,500 shares of the Company's common stock to nine new employees under an inducement stock option where each stock option: has an exercise price per share of $32.70, the closing price of Aegerion's common stock on the grant date; will vest 25% a year after the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten-year term; and is subject to the terms and conditions of the Company's Inducement Award Stock Option Plan and the terms and conditions of a stock option agreement that covers the grant. The full analyst notes on Aegerion Pharmaceuticals are available to download free ofcharge at:
http://www.analystsreview.com/Jul-14-2014/AEGR/report.pdf
Opko Health Inc. Analyst Notes
On July 9, 2014, Opko Health Inc. (OPKO) announced that it received a positive opinion from the European Committee for Orphan Medicinal Products (COMP), recommending the approval of orphan drug designation for OPKO's long-acting version of clotting Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX and the congenital Factor VII deficiency. According to the Company, the previously presented preclinical data by OPKO show that its long-acting Factor VIIa-CTP has demonstrated the potential for substantial improvement of the quality of life of patients, through both IV and subcutaneous (SC) administration. Dr. Phillip Frost, CEO, OPKO, said, "We are pleased that the COMP will recommend orphan designation for Factor VIIa-CTP in the EU, as it would allow OPKO 10 years of marketing exclusivity upon commercialization of the drug." The full analyst notes on OPKO are available to download free of charge at:
http://www.analystsreview.com/Jul-14-2014/OPK/report.pdf
PerkinElmer, Inc. Analyst Notes
On July 7, 2014, PerkinElmer, Inc. (PerkinElmer) announced that it will release its Q2 2014 financial results on Thursday, July 31, 2014, after the market closes, and will also hold a conference call to discuss the results on the same day, at 5:00 p.m. ET., hosted by the Company's Chairman and CEO, Robert F. Friel, and Senior Vice President and CFO, Andy Wilson. According to the Company, the conference call will be webcast live on its website, where a replay will also be accessible beginning at 7:00 p.m. ET, on July 31, 2014. The full analyst notes on PerkinElmer are available to download free of charge at:
http://www.analystsreview.com/Jul-14-2014/PKI/report.pdf
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.comfor consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.AnalystsReview.com
SOURCE Analysts Review
